Control Bionics Ltd. (AU:CBL) has released an update.
Control Bionics Ltd., a medical device company specializing in communication aid technology, has issued over 1.2 million share options to employees and plans to issue additional options to its CEO, pending shareholder approval at the next AGM. The company is expanding its innovative product portfolio, which includes the NeuroNode technology for patients with severe communication disabilities and a newly TGA-approved autonomous wheelchair module, showcasing a commitment to growth in the healthcare and assistive tech industries.
For further insights into AU:CBL stock, check out TipRanks’ Stock Analysis page.
